RGS17 and hearing loss disorder: To investigate the role of RGS17 in cisplatin-induced hearing loss model, we administered siRNA against RGS17 via trans-tympanic route (0.9 μg) into the middle ear of male Wistar rats, two days prior to cisplatin treatment.